Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Ana Maria OrbaiJordi GratacósAnthony TurkiewiczStephen HallEva DokoupilovaBernard CombePeter NashGaia GalloClinton C BertramAmanda M GellettAubrey Trevelin SpraberyJulie BirtLisa MacphersonVladimir J GeneusArnaud ConstantinPublished in: Rheumatology and therapy (2020)
ClinicalTrials.gov identifier: NCT02349295.
Keyphrases